✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Fasiglifam is an investigational drug.
There have been 10 clinical trials for Fasiglifam. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2012.
The most common disease conditions in clinical trials are Diabetes Mellitus, Diabetes Mellitus, Type 2, and Renal Insufficiency, Chronic. The leading clinical trial sponsors are Takeda and [disabled in preview].
Recent Clinical Trials for Fasiglifam
|Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis||Takeda||Phase 3|
|Fasiglifam 25 mg BID vs 50 mg QD||Takeda||Phase 2|
|Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes||Takeda||Phase 3|